Trial reportJournal of the American Society of Nephrology : JASN2012
Correction of postkidney transplant anemia reduces progression of allograft nephropathy.
Trial report in Journal of the American Society of Nephrology : JASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 58 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter, Prospective, Randomised, Open-label Study, Evaluating the Effect of Two Levels of Haemoglobin on Quality of Life and Speed of Progression of Renal Insufficiency on Renal Transplanted Patients With Chronic Graft Dysfunction (CGD)
A Factorial Randomized Controlled Trial of Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients
Who cites it
58 citing papers in PubMed, 6 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease.BMC nephrology · 2025Guideline
- A systematic review and meta-analysis of factors contributing to post-kidney transplant anemia and the effect of erythropoietin-stimulating agents.Systematic reviews · 2024Pooled it
- Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.The Cochrane database of systematic reviews · 2023Pooled it
- Erythropoiesis stimulating agents and reno-protection: a meta-analysis.BMC nephrology · 2017Pooled it
- Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis.Journal of the American Society of Nephrology : JASN · 2015Pooled it
- Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.The Cochrane database of systematic reviews · 2014Pooled it
- Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial.Clinical and experimental nephrology · 2023Trial
- The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019Trial
- Post-transplant anemia as a persistent risk factor for graft dysfunction in kidney transplant recipients.Renal failure · 2026Article
- KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- Early Post-Kidney Transplant Treatment With Roxadustat Ameliorates Anemia and Reduces Blood Transfusion Needs in Inflamed Patients: A Case-Matched Study.Clinical transplantation · 2026Article
- Reporting of patient-reported outcomes (PROs) in randomized controlled trials of anemia treatments for people with CKD: a scoping review.Journal of patient-reported outcomes · 2026Article
- Ongoing and Novel Challenges in Kidney Transplantation: Therapeutic Approaches to Non-Immunological Risk Factors for Allograft Loss.Life (Basel, Switzerland) · 2026Review
- Anemia and iron deficiency in post-kidney transplantation: an unsolved challenge.Clinical kidney journal · 2025Review
- Insights Into Health-Related Quality of Life of Kidney Transplant Recipients: A Narrative Review of Associated Factors.Kidney medicine · 2025Review
- The Safety and Efficacy of Daprodustat for Recipients in Peritransplant Period: a Single-Center Retrospective Study on Post-Transplant Anemia Management in Kidney Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Post-transplant renal anemia: a call to action from a national study in routine clinical practice.Clinical kidney journal · 2024Article
- The Efficacy and Safety of Roxadustat for the Treatment of Posttransplantation Anemia: A Randomized Study.Kidney international reports · 2024Article
- Kidney Transplantation Improves Health-Related Quality of Life in Older Recipients.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Adverse Drug Events after Kidney Transplantation.Journal of personalized medicine · 2023Review
Corrections and comments
- Commented on by
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retrospective studies suggest that chronic allograft nephropathy might progress more rapidly in patients with post-transplant anemia, but whether correction of anemia improves renal outcomes is unknown. An open-label, multicenter, randomized controlled trial investigated the effect of epoetin-β to normalize hemoglobin values (13.0-15.0 g/dl, n=63) compared with partial correction of anemia (10.5-11.5 g/dl, n=62) on progression of nephropathy in transplant recipients with hemoglobin <11.5 g/dl and an estimated creatinine clearance (eCrCl) <50 ml/min per 1.73 m(2). After 2 years, the mean hemoglobin was 12.9 and 11.3 g/dl in the normalization and partial correction groups, respectively (P<0.001). From baseline to year 2, the eCrCl decreased by a mean 2.4 ml/min per 1.73 m(2) in the normalization group compared with 5.9 ml/min per 1.73 m(2) in the partial correction group (P=0.03). Furthermore, fewer patients in the normalization group progressed to ESRD (3 versus 13, P<0.01). Cumulative death-censored graft survival was 95% and 80% in the normalization and partial correction groups, respectively (P<0.01). Complete correction was associated with a significant improvement in quality of life at 6 and 12 months. The number of cardiovascular events was low and similar between groups. In conclusion, this prospective study suggests that targeting hemoglobin values ≥13 g/dl reduces progression of chronic allograft nephropathy in kidney transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.